Malta - English - Medicines Authority

hospira uk limited - meropenem - powder for solution for infusion or injection - meropenem 500 mg - antibacterials for systemic use

Malta - English - Medicines Authority

hospira uk limited - meropenem - powder for solution for infusion or injection - meropenem 1 g - antibacterials for systemic use

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 1140mg equivalent to meropenem 1000mg;   - powder for injection - 1000 mg - active: meropenem trihydrate 1140mg equivalent to meropenem 1000mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 570mg equivalent to meropenem 500mg;   - powder for injection - 500 mg - active: meropenem trihydrate 570mg equivalent to meropenem 500mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.

Malta - English - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - meropenem trihydrate - powder for solution for infusion or injection - meropenem trihydrate 1 g - antibacterials for systemic use

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 1000 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 500 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 500 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g;   - powder for injection - 1 g - active: meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g   excipient: nitrogen sodium carbonate - indicated for treatment, in adults and children, of lower respiratory tract infections.